Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Di Lorenzo
Luigi
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011758:Pyrroles / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D020917:Receptor, trkA / Q000378:metabolism; D015398:Signal Transduction; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D020794:Receptor Protein-Tyrosine Kinases; D020917:Receptor, trkA; D000077210:Sunitinib